News | August 06, 2024
OneSource and BRL ink technology licensing agreement to deliver high-concentration biologics subcutaneously
Revolutionary technology will further boost OneSource’s scientific services offerings
Revolutionary technology will further boost OneSource’s scientific services offerings
BAV has revolutionized the animal vaccination industry with its ground-breaking delivery methods that prioritize quality, safety, and efficacy
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
Vonoprazan is a potassium-competitive acid blocker (P-CAB) used for the treatment of acid-related disorders
Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
The expiry date of almost all strips is rubber stamped vanish in a matter of 3 to 4 months, making the remaining tablets waste for subsequent use before expire date
Vonoprozan is a novel potassium-competitive acid blocker used for the treatment of acid related disorders
This novel recombinant has been developed and is a patented novel recombinant Human Albumin 20% process
Subscribe To Our Newsletter & Stay Updated
